- Investing Ideas
- Taiwanese Pharmaceuticals & Biotech Top Stock Picks from Analysts
Taiwanese Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
7
Companies which are more than 50% undervalued based on analyst price target.
7 companies
Caliway Biopharmaceuticals
Market Cap: NT$159.4b
Engages in the development of drugs for aesthetic medicine and chronic inflammation.
6919
NT$102.50
7D
-7.2%
1Y
-42.3%
Lotus Pharmaceutical
Market Cap: NT$49.7b
Engages in the research and development, manufacture, and sale of generic pharmaceutical products in Taiwan, South Korea, the United States, and internationally.
1795
NT$186.50
7D
-1.1%
1Y
-2.4%
Oneness Biotech
Market Cap: NT$22.7b
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan.
4743
NT$47.35
7D
1.1%
1Y
-29.9%
TaiMed Biologics
Market Cap: NT$17.0b
A biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases.
4147
NT$62.40
7D
-8.9%
1Y
-19.6%
Medigen Vaccine Biologics
Market Cap: NT$17.0b
A biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan.
6547
NT$51.70
7D
2.2%
1Y
33.4%
EirGenix
Market Cap: NT$15.1b
Operates as a contract development and manufacturing company in Taiwan and internationally.
6589
NT$49.85
7D
-2.4%
1Y
-17.3%
Foresee Pharmaceuticals
Market Cap: NT$12.5b
Operates as biopharmaceutical company in the United States, China, and Europe.
6576
NT$79.20
7D
-0.4%
1Y
-3.4%